Solidifying our Leadership in Rare and Highly Specialized Diseases - PowerPoint PPT Presentation

Solidifying our Leadership in Rare and Highly Specialized Diseases Tyler Flemming Ornskov, MD, MPH CEO HAE Jeff Poulton CFO Q3 Results 2016 November 1, 2016

“Safe Harbor” Statement Under The Private Securities Litigation Reform Act Of 1995 Forward-Looking Statements • inability to successfully compete for highly qualified personnel from other companies and organizations; Statements included herein that are not historical facts, including without limitation statements concerning • failure to achieve the strategic objectives with respect to Shire’s acquisition of NPS Pharmaceuticals, future strategy, plans, objectives, expectations and intentions, the anticipated timing of clinical trials and Inc., Dyax Corp. (“Dyax”) or Baxalta Inc. (“Baxalta”) may adversely affect Shire’s financial condition and approvals for, and the commercial potential of, inline or pipeline products are forward-looking statements. results of operations; Such forward-looking statements involve a number of risks and uncertainties and are subject to change at • Shire’s growth strategy depends in part upon its ability to expand its product portfolio through external any time. In the event such risks or uncertainties materialize, Shire’s results could be materially adversely collaborations, which, if unsuccessful, may adversely affect the development and sale of its products; affected. The risks and uncertainties include, but are not limited to, the following: • a slowdown of global economic growth, or economic instability of countries in which Shire does business, as well as changes in foreign currency exchange rates and interest rates, that adversely • Shire’s products may not be a commercial success; impact the availability and cost of credit and customer purchasing and payment patterns, including the • increased pricing pressures and limits on patient access as a result of governmental regulations and collectability of customer accounts receivable; market developments may affect Shire’s future revenues, financial condition and results of operations; • failure of a marketed product to work effectively or if such a product is the cause of adverse side effects • Shire conducts its own manufacturing operations for certain of its products and is reliant on third party could result in damage to the Shire’s reputation, the withdrawal of the product and legal action against contract manufacturers to manufacture other products and to provide goods and services. Some of Shire; Shire’s products or ingredients are only available from a single approved source for manufacture. Any • investigations or enforcement action by regulatory authorities or law enforcement agencies relating to disruption to the supply chain for any of Shire’s products may result in Shire being unable to continue Shire’s activities in the highly regulated markets in which it operates may result in significant legal costs marketing or developing a product or may result in Shire being unable to do so on a commercially viable and the payment of substantial compensation or fines; basis for some period of time; • Shire is dependent on information technology and its systems and infrastructure face certain risks, • the manufacture of Shire’s products is subject to extensive oversight by various regulatory agencies. including from service disruptions, the loss of sensitive or confidential information, cyber-attacks and Regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or other security breaches or data leakages that could have a material adverse effect on Shire’s revenues, manufacturing processes could lead to significant delays, an increase in operating costs, lost product financial condition or results of operations; sales, an interruption of research activities or the delay of new product launches; • Shire incurred substantial additional indebtedness to finance the Baxalta acquisition, which may • certain of Shire’s therapies involve lengthy and complex processes, which may prevent Shire from decrease its business flexibility and increase borrowing costs; timely responding to market forces and effectively managing its production capacity; • difficulties in integrating Dyax or Baxalta into Shire may lead to the combined company not being able • Shire has a portfolio of products in various stages of research and development. The successful to realize the expected operating efficiencies, cost savings, revenue enhancements, synergies or other development of these products is highly uncertain and requires significant expenditures and time, and benefits at the time anticipated or at all; and there is no guarantee that these products will receive regulatory approval; Other risks and uncertainties detailed from time to time in Shire’s filings with the Securities and Exchange • the actions of certain customers could affect Shire’s ability to sell or market products profitably. Commission, including those risks outlined in “ITEM 1A: Risk Factors” in Shire’s Quarterly Report on Form Fluctuations in buying or distribution patterns by such customers can adversely affect Shire’s revenues, 10-Q for the quarter ended June 30, 2016. financial conditions or results of operations; All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified • Shire’s products and product candidates face substantial competition in the product markets in which it in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on these operates, including competition from generics; forward-looking statements that speak only as of the date hereof. Except to the extent otherwise required • adverse outcomes in legal matters, tax audits and other disputes, including Shire’s ability to enforce by applicable law, we do not undertake any obligation to update or revise forward-looking statements, and defend patents and other intellectual property rights required for its business, could have a material whether as a result of new information, future events or otherwise. adverse effect on the combined company’s revenues, financial condition or results of operations; 2

Agenda 1. Business update Flemming Ornskov, MD, MPH Delivering, Integrating, Upgrading and Innovating 2. Financial review Jeff Poulton 3. Summary Flemming Ornskov, MD, MPH 4. Q & A All 3

Solidifying our leadership in rare and highly specialized diseases Delivering Integrating Upgrading Innovating • Record product sales • Integration proceeding ahead • Upgrading execution of • New product approvals performance of relevant benchmarks Baxalta franchises using the (CUVITRU & ONIVYDE) Shire commercial platform and key product launches • Strong growth from legacy • Ahead of synergy target (XIIDRA & VONVENDI) Shire products, including YTD, and on-track for • Combined approach for since Q2 results XIIDRA launch Year 3 guidance commercial ops, market access, patient services • Driving late stage, global • Remain on target and on • Manufacturing network assets such as SHP643 track to deliver our optimization underway • Expanding geographic (HAE) and SHP647 (IBD) non GAAP full year 2016 reach of our product portfolio guidance and services • Innovative clinical pipeline with promising late-stage programs 4

Delivering: Record product sales and Non-GAAP earnings with Baxalta acquisition and supported by performance of legacy Shire franchises Financial highlights • Addition of first full quarter of Baxalta franchises has led Product Sales to record product sales of $3.3B $3,315M • As expected, pro forma sales growth was at the mid Q3 2016 111% CER (1)(2) single digit level against a strong comparative period; $1,577M • Legacy Shire franchises delivered 12% growth, while Q3 2015 legacy Baxalta franchise growth of -1% was impacted by the timing of large orders • Non GAAP diluted earnings per ADS decreased year on year, primarily due to higher Non GAAP operating Non GAAP Diluted Earnings per ADS (2)(3) income being more than offset by the impact of a higher $3.17 number of shares issued as consideration for the Baxalta transaction. Q3 2016 -3% CER (1)(2) $3.24 • We remain on target and track to deliver our full year 2016 guidance, which was recently upgraded at Q2 Q3 2015 earnings (1) Growth rates are at Constant exchange rates (“CER”), a Non GAAP financial measure. CER performance is determined by comparing 2016 performance (restated using 2015 exchange rates for the relevant period) to actual 2015 reported performance. 5 (2) See slide 36 for a list of items excluded from the US GAAP equivalent used to calculate all Non GAAP measures detailed above. See slides 32 to 35 for a reconciliation of Non GAAP financial measures to the most directly comparable measure under US GAAP. (3) This is a Non GAAP financial measure. The most directly comparable measure under US GAAP is EPS-ADS (Q3 2016: -$1.29, Q3 2015: $2.29).